1. Introduction {#sec1-pharmacy-07-00124}
===============

Antibiotics are one of the most common causes of life-threatening medication allergies \[[@B1-pharmacy-07-00124]\]. These allergic reactions can be broadly categorized into immediate (IgE-mediated) or non-immediate reactions (T cell-mediated). Patients with immediate allergic reactions can present clinical manifestations that include urticaria, angioedema, and anaphylaxis, whereas those with non-immediate reactions can present symptoms ranging from contact dermatitis to a maculopapular rash \[[@B1-pharmacy-07-00124]\]. A vast number of hypersensitivity reactions have been reported from the beta-lactam class (up to 15% of patients), but allergic reactions from aminoglycosides are less frequently reported (\<2%) \[[@B1-pharmacy-07-00124],[@B2-pharmacy-07-00124]\]. Similar to beta-lactam antibiotics, non-immediate reactions to aminoglycosides are more commonly seen \[[@B2-pharmacy-07-00124]\]. Contact dermatitis from topical aminoglycoside use is the most frequently reported reaction with aminoglycosides, even when compared with other topical medications \[[@B3-pharmacy-07-00124],[@B4-pharmacy-07-00124]\]. Due to the infrequent nature of aminoglycoside allergies, a review of the current literature on aminoglycoside hypersensitivity reactions and associated management is lacking. This paper will review the medicinal chemistry, indications, reported allergic reactions, and desensitization protocols associated with aminoglycoside utilization.

2. Medicinal Chemistry {#sec2-pharmacy-07-00124}
======================

2.1. Aminoglycoside Structure {#sec2dot1-pharmacy-07-00124}
-----------------------------

The structure of aminoglycosides consists of a hexose ring, to which various amino sugars are attached via glycosidic linkages. Aminoglycosides can be classified into two main structural classes based on the aminocylitol nucleus: streptidine (streptomycin) and deoxystrepatamine (gentamicin, tobramycin, amikacin, kanamycin, neomycin, and plazomicin) ([Figure 1](#pharmacy-07-00124-f001){ref-type="fig"}). Irrespective of their structural differences, all aminoglycosides exhibit concentration-dependent bactericidal activity through inhibition of protein synthesis. The structural difference seems to play an important role in escaping the bacterial resistance mechanisms, especially by offering structural robustness against metabolizing enzymes, such as Aminoglycoside Modifying Enzymes (AMEs), and target-modifying 16S rRNA methyl transferases (16S-RMTases), produced by the bacteria \[[@B5-pharmacy-07-00124]\]. Amikacin and plazomicin have been shown to have increased stability against AMEs compared to gentamicin \[[@B5-pharmacy-07-00124]\]. All currently marketed aminoglycosides are affected by 16S-RMTases, rendering them inactive against the organisms producing the enzyme \[[@B5-pharmacy-07-00124]\].

2.2. Structural Aspects behind Cross-Reactivity {#sec2dot2-pharmacy-07-00124}
-----------------------------------------------

Neomycin has antigenic properties possessing diamino sugars called neosamines in its structure. Similar diamino sugars with minor modifications are present in kanamycin and tobramycin. As a result of the structural similarity between tobramycin and neomycin, up to 65% of patients allergic to neomycin are shown to have a cross-allergic reaction to tobramycin \[[@B6-pharmacy-07-00124]\]. [Figure 2](#pharmacy-07-00124-f002){ref-type="fig"} shows the structural constituents of neomycin B. Kanamycin has also been shown to have cross-sensitivity with neomycin, owing to the presence of neosamine-like groups in its structure \[[@B7-pharmacy-07-00124]\]. Gentamicin has also shown cross-reactivity with neomycin. In the case of gentamicin, the antigenicity is contributed by the deoxystreptamine group in its structure, which is also present in neomycin \[[@B8-pharmacy-07-00124]\]. Generally speaking, cross-reactivity among aminoglycosides with the deoxystreptamine group (gentamicin, tobramycin, amikacin, kanamycin, neomycin, and plazomicin) is at least 50% \[[@B9-pharmacy-07-00124]\]. For this reason, all deoxystreptamine-containing aminoglycosides carry a contraindication against use if a patient has a known hypersensitivity to another deoxystreptamine-containing aminoglycoside \[[@B10-pharmacy-07-00124],[@B11-pharmacy-07-00124],[@B12-pharmacy-07-00124],[@B13-pharmacy-07-00124]\].

As mentioned above, cross-reactivity is due to specific functional groups present in these antibiotics. Cross-reactivity between the deoxystreptamine-containing aminoglycosides and streptidine-containing streptomycin has not been observed. Streptidine in streptomycin is responsible for its antigenicity; therefore, deoxystreptamine-sensitive individuals are less likely to develop allergic cross-reactions to streptomycin therapy \[[@B14-pharmacy-07-00124]\].

3. Medical Conditions for Which Aminoglycosides Are Used {#sec3-pharmacy-07-00124}
========================================================

Aminoglycosides are useful in the treatment of a wide variety of diseases, primarily infections caused by Gram-negative aerobic bacilli, typically in combination with another antimicrobial or as monotherapy for urinary tract infections ([Table 1](#pharmacy-07-00124-t001){ref-type="table"}) \[[@B10-pharmacy-07-00124],[@B11-pharmacy-07-00124],[@B12-pharmacy-07-00124],[@B15-pharmacy-07-00124],[@B16-pharmacy-07-00124],[@B17-pharmacy-07-00124]\]. Aminoglycoside monotherapy has been associated with a significantly higher rate of bacteriological failure at the end of therapy in the treatment of nonurinary sources (e.g., pneumonia, abscess, central nervous system, etc.) \[[@B18-pharmacy-07-00124],[@B19-pharmacy-07-00124]\].

Gentamicin has activity against many Gram-negative organisms such as all Enterobacteriaceae spp. (except Providencia stuartii), Pseudomonas aeruginosa, Aeromonas spp., Haemophilus influenzae, Brucella spp., Moraxella spp., Pasturella multocida, and Francisella tularensis, and occasionally Acinetobacter baumannii \[[@B11-pharmacy-07-00124],[@B16-pharmacy-07-00124]\]. Gentamicin and tobramycin can be given in combination with other cell wall-active antimicrobials in order to capitalize on their synergistic action against Gram-positive organisms \[[@B16-pharmacy-07-00124],[@B17-pharmacy-07-00124]\]; gentamicin has synergistic activity in combination with beta-lactams or vancomycin against several Gram-positive organisms (e.g., Bacillus spp., Enterococcus faecalis, Listeria monocytogenes, Staphylococcus aureus, Streptococcus spp.) \[[@B16-pharmacy-07-00124]\]. Compared to gentamicin, tobramycin has similar activity against many Gram-negative organisms, such as all Enterobacteriaceae spp. (except Providencia stuartii), and Haemophilus influenzae; however, it has higher potency against Pseudomonas aeruginosa and Acinetobacter baumannii \[[@B12-pharmacy-07-00124],[@B17-pharmacy-07-00124],[@B20-pharmacy-07-00124],[@B21-pharmacy-07-00124],[@B22-pharmacy-07-00124]\]. Tobramycin has little activity against Gram-positive organisms, but may be given in combination with cell wall-active agents for treatment of E. faecalis-associated infections \[[@B17-pharmacy-07-00124]\]. Compared to tobramycin, amikacin has activity against all Enterobacteriaceae spp., H. influenzae, P. multocida, and higher potency against Pseudomonas aeruginosa and Acinetobacter baumannii \[[@B10-pharmacy-07-00124],[@B15-pharmacy-07-00124]\]. Amikacin may have activity against many Mycobacterium spp., Staphylococci spp., and Nocardia asteroids \[[@B15-pharmacy-07-00124]\]. Plazomicin, the newest aminoglycoside, has activity against extended-spectrum beta-lactamase-producing and carbapenem-resistant Enterobacteriaceae spp., and is reserved for patients with limited or no other treatment options \[[@B13-pharmacy-07-00124],[@B23-pharmacy-07-00124]\].

In addition to parenteral administration for systemic infections, most aminoglycosides come in other dosage forms that are used clinically. For example, gentamicin and tobramycin are available in topical dosage forms to treat ophthalmic, otic, and skin infections \[[@B21-pharmacy-07-00124],[@B22-pharmacy-07-00124],[@B24-pharmacy-07-00124],[@B25-pharmacy-07-00124],[@B26-pharmacy-07-00124]\]. They are also included in bone cement and beads to prevent and treat bone and joint infections \[[@B27-pharmacy-07-00124]\]. Tobramycin and amikacin are available in inhaled dosage forms, such as a nebulizer solution and an inhalation powder or suspension, to treat pulmonary infections \[[@B20-pharmacy-07-00124],[@B28-pharmacy-07-00124]\].

If the patient has an IgE-mediated aminoglycoside allergy or fails or refuses drug desensitization (described later), then a provider should select empiric or targeted alternative therapies deemed appropriate for the type and cause of the infection. The most likely alternative would be another broad-spectrum agent (e.g., beta-lactam/beta-lactamase inhibitor, fourth generation cephalosporin, carbapenem, tetracycline, or macrolide).

4. Documented Allergic Reactions {#sec4-pharmacy-07-00124}
================================

Overall, allergic reactions to aminoglycosides reported in the literature are rare. Aminoglycosides come in multiple dosage forms, including topical, parenteral, and inhaled, and there have been reports of reactions from each dosage form, some being localized reactions, and others being systemic reactions \[[@B30-pharmacy-07-00124],[@B31-pharmacy-07-00124],[@B32-pharmacy-07-00124],[@B33-pharmacy-07-00124],[@B34-pharmacy-07-00124],[@B35-pharmacy-07-00124],[@B36-pharmacy-07-00124],[@B37-pharmacy-07-00124],[@B38-pharmacy-07-00124],[@B39-pharmacy-07-00124],[@B40-pharmacy-07-00124],[@B41-pharmacy-07-00124],[@B42-pharmacy-07-00124],[@B43-pharmacy-07-00124],[@B44-pharmacy-07-00124],[@B45-pharmacy-07-00124],[@B46-pharmacy-07-00124],[@B47-pharmacy-07-00124],[@B48-pharmacy-07-00124],[@B49-pharmacy-07-00124],[@B50-pharmacy-07-00124],[@B51-pharmacy-07-00124],[@B52-pharmacy-07-00124],[@B53-pharmacy-07-00124],[@B54-pharmacy-07-00124],[@B55-pharmacy-07-00124],[@B56-pharmacy-07-00124],[@B57-pharmacy-07-00124],[@B58-pharmacy-07-00124],[@B59-pharmacy-07-00124]\]. Below and in [Table 2](#pharmacy-07-00124-t002){ref-type="table"}, [Table 3](#pharmacy-07-00124-t003){ref-type="table"} and [Table 4](#pharmacy-07-00124-t004){ref-type="table"} is a summary of the reactions caused by gentamicin, tobramycin, and amikacin. No allergic reactions to the newest aminoglycoside, plazomicin, were found in the literature. Most reported reactions occurred in children or patients over the age of 55 years, and most were confirmed via a patch test or a rechallenge. Additionally, many of the reactions involved a patient who had received a prior aminoglycoside, usually as a topical or ophthalmic dosage form. Most patients described were switched to an alternative antibiotic with resolution of symptoms; other patients underwent desensitization to the aminoglycoside.

The most frequently reported type of allergic reaction for gentamicin, tobramycin, and amikacin was cutaneous, and the reactions were caused by a variety of dosage forms ([Table 2](#pharmacy-07-00124-t002){ref-type="table"}). For gentamicin, there were reports of allergic dermatitis, contact sensitivity, ulcerative dermatitis, urticaria, rash, and exfoliative erythroderma \[[@B30-pharmacy-07-00124],[@B31-pharmacy-07-00124],[@B32-pharmacy-07-00124],[@B33-pharmacy-07-00124],[@B34-pharmacy-07-00124],[@B35-pharmacy-07-00124],[@B36-pharmacy-07-00124],[@B37-pharmacy-07-00124],[@B38-pharmacy-07-00124],[@B39-pharmacy-07-00124],[@B40-pharmacy-07-00124]\]. Reported cutaneous reactions with tobramycin included contact dermatitis, exfoliative dermatitis, rash, urticaria, toxic epidermal necrosis (given concomitantly with meropenem), Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome (given concomitantly with piperacillin/tazobactam), and fixed exanthema \[[@B40-pharmacy-07-00124],[@B41-pharmacy-07-00124],[@B42-pharmacy-07-00124],[@B43-pharmacy-07-00124],[@B44-pharmacy-07-00124],[@B45-pharmacy-07-00124],[@B46-pharmacy-07-00124],[@B47-pharmacy-07-00124],[@B48-pharmacy-07-00124]\]. The only skin-related reaction to amikacin reported was DRESS \[[@B49-pharmacy-07-00124]\].

There are reports of anaphylaxis with both gentamicin and amikacin, and all of these cases result from parenteral use of the drug ([Table 3](#pharmacy-07-00124-t003){ref-type="table"}) \[[@B50-pharmacy-07-00124],[@B51-pharmacy-07-00124],[@B52-pharmacy-07-00124],[@B53-pharmacy-07-00124],[@B54-pharmacy-07-00124],[@B55-pharmacy-07-00124]\]. Two of the case reports involving gentamicin identified that the patient had previous been treated with at least one aminoglycoside, which could have caused the sensitization. Interestingly, both of these reports implicated either a topical dosage form or the use of gentamicin in bone cement, not a previous parenteral administration of an aminoglycoside, as the cause of sensitization \[[@B51-pharmacy-07-00124],[@B54-pharmacy-07-00124]\].

[Table 4](#pharmacy-07-00124-t004){ref-type="table"} summarizes other allergic reactions that have been reported to aminoglycosides \[[@B47-pharmacy-07-00124],[@B56-pharmacy-07-00124],[@B57-pharmacy-07-00124],[@B58-pharmacy-07-00124],[@B59-pharmacy-07-00124]\]. Bronchospasms with or without other signs and symptoms (eosinophilia, urticaria, pruritus) have been reported with use of tobramycin. One case report described a patient who experienced bronchospasm with eosinophilia, with inhaled tobramycin \[[@B58-pharmacy-07-00124]\]. Another case report described a patient with bronchospasm, urticaria, and pruritus after receiving intravenous tobramycin \[[@B59-pharmacy-07-00124]\]. The case report describing bronchospasm without any other signs and symptoms occurred after ocular administration of tobramycin \[[@B57-pharmacy-07-00124]\]. Other reported reactions with tobramycin included arthralgia and fever \[[@B47-pharmacy-07-00124]\]. A reported reaction with questionable attribution to gentamicin (due to concomitant administration with penicillin) was serum sickness \[[@B56-pharmacy-07-00124]\].

5. Desensitization {#sec5-pharmacy-07-00124}
==================

Antimicrobial desensitization procedures have been conducted since the 1940s and are more commonly completed in patients with allergic reactions to penicillin antibiotics \[[@B4-pharmacy-07-00124]\]. Desensitization typically requires several hours to complete, and can be accomplished through administration of incremental doses of an antimicrobial agent, resulting in immune tolerance to that antimicrobial. Due to the infrequent nature of aminoglycoside allergies, desensitization procedures are not generally performed, but limited data, restricted to case reports and case series, have demonstrated success when utilized \[[@B38-pharmacy-07-00124],[@B40-pharmacy-07-00124],[@B47-pharmacy-07-00124],[@B59-pharmacy-07-00124]\].

Four articles were identified describing desensitization protocols and outcomes in patients with aminoglycoside allergies \[[@B38-pharmacy-07-00124],[@B40-pharmacy-07-00124],[@B47-pharmacy-07-00124],[@B59-pharmacy-07-00124]\]. All desensitization procedures were conducted in patients with cystic fibrosis requiring tobramycin administration. Earl et al. described a tobramycin desensitization due to a case of urticarial reactions to both beta-lactam and aminoglycoside antibiotics in a 15-year-old patient receiving treatment for a left upper-lobe lung abscess \[[@B40-pharmacy-07-00124]\]. The patient had a history of pulmonary infection due to *Pseudomonas* sp. and experienced generalized urticaria to both intravenous and inhaled tobramycin therapy. Prior to desensitization, the patient received pretreatment with theophylline and inhaled isoproterenol to suppress any pulmonary responses. Antihistamines were not administered due to the risk of masking early cutaneous reactions from tobramycin. The initial dose of tobramycin during the desensitization protocol was 1 mcg diluted in 20 mL of normal saline, and given intravenously over 20 min. Ten minutes after the end of the infusion, the patient received double the amount of tobramycin as provided in the previous dose. This procedure was repeated 17 times over eight hours until a cumulative dose of 80 mg of tobramycin was given. No reactions were noted, with the exception of a transient rash after doses 9 (0.256 mg) and 10 (0.512 mg) of tobramycin. The patient ultimately received 80 mg of intravenous tobramycin every six hours and did not experience any allergic reactions for the remainder of treatment \[[@B40-pharmacy-07-00124]\].

The protocol by Earl et al. was also used by Schretlen-Doherty et al. in an 18-year-old male for treatment of a cystic fibrosis exacerbation \[[@B59-pharmacy-07-00124]\]. This patient developed shaking, rash, and pruritus secondary to intravenous tobramycin administration. After desensitization, no allergic reactions were noted for the remainder of the 14-day course \[[@B59-pharmacy-07-00124]\].

Similar success was found in a retrospective review of patients that underwent tobramycin desensitization \[[@B47-pharmacy-07-00124]\]. Seven out of eight (88%) patients successfully completed tobramycin desensitization; one person felt unwell and experienced fever during desensitization and was unable to complete the full desensitization protocol. This desensitization protocol differed from the protocol discussed previously; this protocol utilized a seven-step approach over 140 min, with 10-fold increases in tobramycin doses. Additionally, oral antihistamines and steroids were provided as pretreatment at the discretion of the provider \[[@B47-pharmacy-07-00124]\].

Spigarelli et al. described their experience with an inhaled tobramycin desensitization protocol in a 9-year-old cystic fibrosis patient with pulmonary exacerbation \[[@B38-pharmacy-07-00124]\]. The patient had a history of rash when administered intravenous gentamicin, and developed a rash during inhaled tobramycin therapy. As part of the desensitization protocol, the patient underwent 15 treatments every 2 h via nebulizer. The initial dose was 0.3 mg of tobramycin in 5 mL of normal saline; subsequent doses were gradually increased until the full dose of 300 mg was administered \[[@B38-pharmacy-07-00124]\]. No adverse reactions were noted during the desensitization protocol and pulmonary function tests were not performed as respiratory symptoms were not exhibited by the patient. After desensitization was completed, the patient received nine months of tobramycin inhalation therapy without any complications or signs of rash or fever \[[@B38-pharmacy-07-00124]\].

6. Conclusions {#sec6-pharmacy-07-00124}
==============

Allergic reactions due to aminoglycoside use are infrequently reported, with non-immediate, cutaneous reactions being the most commonly reported. Strategies to overcome hypersensitivity reactions, such as desensitization, have been utilized with successful outcomes. It is prudent to change to an alternative antibiotic if the patient experiences an immediate hypersensitivity reaction (e.g., anaphylaxis, hives), and changing antibiotics can be considered for other reactions, such as rash.

Currently available aminoglycosides are similar in structure and are likely to cause cross-reactivity. For this reason, if a patient has a hypersensitivity reaction to one aminoglycoside, the patient should not receive another aminoglycoside, unless a desensitization protocol has been instituted. Despite the small risk of allergic reactions to aminoglycosides, they still have clinical utility for a number of infectious conditions.
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pharmacy-07-00124-t001_Table 1

###### 

Summary of FDA approved and unapproved clinical uses of aminoglycosides.

  Clinical Uses                                                                                                                                                            Aminoglycosides Indicated   Comments
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------ --------------------------- ---------------------------------------------------------------------------------------------------------------
  **FDA Approved Uses**                                                                                                                                                                                
  Bacterial meningitis and CNS \[[@B10-pharmacy-07-00124],[@B11-pharmacy-07-00124],[@B12-pharmacy-07-00124],[@B29-pharmacy-07-00124]\]                                     AMK, GEN, TOB               
  Bacterial sepsis \[[@B10-pharmacy-07-00124],[@B11-pharmacy-07-00124],[@B12-pharmacy-07-00124],[@B29-pharmacy-07-00124]\]                                                 AMK, GEN, TOB               
  Bone and joint \[[@B10-pharmacy-07-00124],[@B11-pharmacy-07-00124],[@B12-pharmacy-07-00124],[@B29-pharmacy-07-00124]\]                                                   AMK, GEN, TOB               
  Burn \[[@B11-pharmacy-07-00124],[@B29-pharmacy-07-00124]\]                                                                                                               AMK                         
  Cystic fibrosis-associated respiratory tract infection \[[@B10-pharmacy-07-00124],[@B12-pharmacy-07-00124],[@B20-pharmacy-07-00124],[@B29-pharmacy-07-00124]\]           AMK, TOB                    
  Intra-abdominal including peritonitis \[[@B10-pharmacy-07-00124],[@B11-pharmacy-07-00124],[@B12-pharmacy-07-00124],[@B20-pharmacy-07-00124],[@B29-pharmacy-07-00124]\]   AMK, GEN, TOB               In combination with agent with Gram-positive and anaerobic activity
  Ocular \[[@B21-pharmacy-07-00124],[@B22-pharmacy-07-00124],[@B24-pharmacy-07-00124],[@B25-pharmacy-07-00124],[@B29-pharmacy-07-00124]\]                                  GEN, TOB                    
  Otic (external) \[[@B26-pharmacy-07-00124]\]                                                                                                                             GEN                         
  Refractory MAC lung disease \[[@B28-pharmacy-07-00124]\]                                                                                                                 ALIS                        In combination antibacterial drug regimen with limited or no alternative treatment options
  Lower respiratory tract (severe) \[[@B10-pharmacy-07-00124],[@B11-pharmacy-07-00124],[@B12-pharmacy-07-00124],[@B29-pharmacy-07-00124]\]                                 AMK, GEN, TOB               In combination with beta-lactam, beta-lactam/beta-lactamase inhibitor, or 3rd or 4th generation cephalosporin
  Skin and soft tissue \[[@B10-pharmacy-07-00124],[@B11-pharmacy-07-00124],[@B12-pharmacy-07-00124],[@B29-pharmacy-07-00124]\]                                             AMK, GEN,                   
  Urinary tract (severe, complicated) \[[@B10-pharmacy-07-00124],[@B11-pharmacy-07-00124],[@B12-pharmacy-07-00124],[@B13-pharmacy-07-00124],[@B29-pharmacy-07-00124]\]     AMK, GEN, TOB, PLZ          
  Post-operative \[[@B10-pharmacy-07-00124]\]                                                                                                                              AMK                         
  **FDA Unapproved Indications**                                                                                                                                                                       
  Actinomycosis \[[@B15-pharmacy-07-00124]\]                                                                                                                               AMK                         
  Bacterial endocarditis \[[@B29-pharmacy-07-00124]\]                                                                                                                      AMK, GEN                    In combination with beta-lactam or vancomycin
  Brucellosis \[[@B16-pharmacy-07-00124]\]                                                                                                                                 GEN                         
  Decontamination of GIT \[[@B16-pharmacy-07-00124]\]                                                                                                                      GEN                         
  Febrile neutropenia (adjunct) \[[@B29-pharmacy-07-00124]\]                                                                                                               AMK, GEN, TOB               In combination therapy
  Female genital infection \[[@B29-pharmacy-07-00124]\]                                                                                                                    GEN                         
  Impregnated cement and beads \[[@B27-pharmacy-07-00124]\]                                                                                                                GEN, TOB                    
  Mycobacteriosis \[[@B29-pharmacy-07-00124]\]                                                                                                                             AMK                         In combination therapy
  Ménière's disease \[[@B16-pharmacy-07-00124],[@B29-pharmacy-07-00124]\]                                                                                                  GEN                         
  Necrotizing enterocolitis in fetus or newborn \[[@B29-pharmacy-07-00124]\]                                                                                               GEN                         
  Nocardiosis \[[@B29-pharmacy-07-00124]\]                                                                                                                                 AMK                         
  Pelvic inflammatory disease (severe) \[[@B29-pharmacy-07-00124]\]                                                                                                        GEN                         In combination with clindamycin
  Plague \[[@B16-pharmacy-07-00124],[@B29-pharmacy-07-00124]\]                                                                                                             GEN                         
  Surgical prophylaxis \[[@B16-pharmacy-07-00124],[@B29-pharmacy-07-00124]\]                                                                                               GEN, TOB                    
  Tularemia \[[@B16-pharmacy-07-00124],[@B29-pharmacy-07-00124]\]                                                                                                          GEN                         
  Uterus (peripartum, postnatal) \[[@B29-pharmacy-07-00124]\]                                                                                                              GEN                         

Abbreviations: ALIS = amikacin liposome inhalation suspension; AMK = amikacin; CNS = central nervous system; FDA = Food and Drug Administration; GEN = gentamicin; GIT = gastrointestinal tract; MAC = *Mycobacterium avium* complex; PLZ = plazomicin; TOB = tobramycin.

pharmacy-07-00124-t002_Table 2

###### 

Cutaneous reactions to aminoglycosides.

  Aminoglycoside Implicated                                                                Reaction                                                   Patient Demographics           Dosage Form                                                                      Concomitant Drugs               Patch Test or Rechallenge Confirm Aminoglycoside Allergy?   Sensitization to Previous Dosage Form of Aminoglycoside?
  ---------------------------------------------------------------------------------------- ---------------------------------------------------------- ------------------------------ -------------------------------------------------------------------------------- ------------------------------- ----------------------------------------------------------- ----------------------------------------------------------
  Gentamicin                                                                               Allergic Dermatitis \[[@B30-pharmacy-07-00124]\]           84-year-old female             Intravenous                                                                      None                            Yes                                                         Yes, topical
  Allergic Dermatitis \[[@B31-pharmacy-07-00124]\]                                         74-year-old female                                         Bone cement                    None                                                                             Yes                             Yes, ongoing bone cement                                    
  Allergic Dermatitis \[[@B32-pharmacy-07-00124]\]                                         30-year-old female                                         Intravenous                    Ampicillin, bupivacaine, lidocaine, ketorolac, pethidine, metamizole magnesium   Yes                             Yes, topical                                                
  Allergic Dermatitis \[[@B33-pharmacy-07-00124]\]                                         55-year-old female                                         Ophthalmic solution            None                                                                             Yes                             Yes, ophthalmic                                             
  Allergic Dermatitis \[[@B34-pharmacy-07-00124]\]                                         79-year-old                                                Intra-articular                None                                                                             Yes                             Yes, ophthalmic                                             
  Contact Dermatitis \[[@B35-pharmacy-07-00124]\]                                          5 newborns                                                 Ophthalmic ointment            Unknown                                                                          Unknown                         Unknown                                                     
  Contact Sensitivity \[[@B36-pharmacy-07-00124]\]                                         50-year-old male                                           Ophthalmic solution            None                                                                             Yes                             Yes, ophthalmic                                             
  Exfoliative Erythroderma \[[@B37-pharmacy-07-00124]\]                                    66-year-old male                                           Intravenous                    Ceftozoxime                                                                      Yes                             Yes, otic                                                   
  Rash \[[@B38-pharmacy-07-00124]\]                                                        9-year-old male                                            Intravenous                    Piperacillin/tazobactam                                                          Unknown                         Unknown                                                     
  Ulcerative Dermatitis \[[@B39-pharmacy-07-00124]\]                                       26 newborns                                                Ophthalmic ointment            Unknown                                                                          Unknown                         Unknown                                                     
  Gentamicin and Tobramycin, different episodes                                            Urticaria \[[@B40-pharmacy-07-00124]\]                     15-year-old female             Intravenous                                                                      None                            Yes                                                         Unknown
  Tobramycin                                                                               Allergic Contact Dermatitis \[[@B41-pharmacy-07-00124]\]   32-year-old female             Otic drops                                                                       Betamethasone, sulfamethazine   Yes                                                         Unknown
  Conjunctivitis \[[@B42-pharmacy-07-00124]\]                                              59-year-old female                                         Ophthalmic suspension          Dexamethasone, atropine, timolol, brominidine, lanatoprost, brinzolamide         Yes                             Unknown                                                     
  Conjunctivitis \[[@B43-pharmacy-07-00124]\]                                              70-year-old female                                         Ophthalmic ointment            Loxacin, homatropine hydrobromide, tropicamide, phenylephrine, diclofenac        Yes                             Unknown                                                     
  Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) \[[@B44-pharmacy-07-00124]\]   4-year-old female                                          Intravenous                    Piperacillin/tazobactam                                                          Unknown                         Unknown                                                     
  Erythroderma, Exfoliative dermatitis \[[@B45-pharmacy-07-00124]\]                        55-year-old woman                                          Intravenous, Intraperitoneal   Vancomcyin, clindamycin                                                          Yes                             Unknown                                                     
  Fixed exanthema \[[@B46-pharmacy-07-00124]\]                                             69-year-old female                                         Intramuscular                  None                                                                             No                              Yes, ophthalmic                                             
  Rash \[[@B38-pharmacy-07-00124]\]                                                        9-year-old male                                            Inhaled                        Pancre-lipase, ADEK vitamins, rh DNAse, albuterol                                Yes                             Yes, Intravenous                                            
  Rash \[[@B47-pharmacy-07-00124]\]                                                        3 patients                                                 Unknown                        Unknown                                                                          Unknown                         Unknown                                                     
  Toxic epidermal necrosis \[[@B48-pharmacy-07-00124]\]                                    42-year-old male                                           Intravenous                    Meropenem, vancomycin, oseltamivir, ciprofloxacin                                Unknown                         Unknown                                                     
  Urticaria \[[@B47-pharmacy-07-00124]\]                                                   3 patients                                                 Unknown                        Unknown                                                                          Unknown                         Unknown                                                     
  Amikacin                                                                                 DRESS \[[@B49-pharmacy-07-00124]\]                         42-year-old male               Intravenous                                                                      Clindamycin, vancomycin         Yes                                                         Unknown

pharmacy-07-00124-t003_Table 3

###### 

Anaphylactic reactions to aminoglycosides.

  Aminoglycoside Implicated                             Reaction                                   Patient Demographics   Dosage Form                                                                                       Concomitant Drugs   Patch Test or Rechallenge Confirm Aminoglycoside Allergy?   Sensitization to Previous Dosage Form of Aminoglycoside?
  ----------------------------------------------------- ------------------------------------------ ---------------------- ------------------------------------------------------------------------------------------------- ------------------- ----------------------------------------------------------- ----------------------------------------------------------
  Gentamicin                                            Anaphylaxis \[[@B50-pharmacy-07-00124]\]   66-year-old female     Intravenous                                                                                       None                Unknown                                                     Unknown
  Anaphylaxis \[[@B51-pharmacy-07-00124]\]              70-year-old female                         Intravenous            Cefotiam                                                                                          Yes                 Yes, topical                                                
  Anaphylaxis, Urticaria \[[@B52-pharmacy-07-00124]\]   69-year-old male                           Intravenous            Midazolam                                                                                         Yes                 Unknown                                                     
  Anaphylaxis \[[@B53-pharmacy-07-00124]\]              53-year-old female                         Intramuscular          None                                                                                              Yes                 Unknown                                                     
  Anaphylaxis \[[@B54-pharmacy-07-00124]\]              66-year-old female                         Intravenous            Chlorhexidine, bupivacaine, dexamethasone, remifentanil, cisatracurium, suxamethonium, propofol   Yes                 Yes, bone cement                                            
  Amikacin                                              Anaphylaxis \[[@B55-pharmacy-07-00124]\]   Newborn male           Intravenous                                                                                       None                Unknown                                                     Unknown

pharmacy-07-00124-t004_Table 4

###### 

Other reactions to aminoglycosides.

  Aminoglycoside Implicated                                        Reaction                                      Patient Demographics   Dosage Form                                                                                 Concomitant Drugs       Patch Test or Rechallenge Confirm Aminoglycoside Allergy?   Sensitization to Previous Dosage Form of Aminoglycoside?
  ---------------------------------------------------------------- --------------------------------------------- ---------------------- ------------------------------------------------------------------------------------------- ----------------------- ----------------------------------------------------------- ----------------------------------------------------------
  Gentamicin                                                       Serum Sickness \[[@B56-pharmacy-07-00124]\]   3-year-old male        Intravenous                                                                                 Penicillin G, aspirin   Unknown                                                     Unknown
  Tobramycin                                                       Arthralgia \[[@B47-pharmacy-07-00124]\]       1 patient              Unknown                                                                                     Unknown                 Unknown                                                     Unknown
  Bronchospasm \[[@B57-pharmacy-07-00124]\]                        79-year-old female                            Ophthalmic ointment    Phenylephrine, prednisolone                                                                 Unknown                 Unknown                                                     
  Bronchospasm, eosinophilia \[[@B58-pharmacy-07-00124]\]          6-year-old male                               Inhaled, Intravenous   Unknown                                                                                     Unknown                 Yes, Inhaled                                                
  Bronchospasm, urticaria, pruritus \[[@B59-pharmacy-07-00124]\]   18-year-old male                              Intravenous            Albuterol, cromolyn, DNAase, pancreatic enzymes, phytonadione, multivitamins, ceftazidime   Unknown                 Yes, Intravenous                                            
  Fever \[[@B47-pharmacy-07-00124]\]                               1 patient                                     Unknown                Unknown                                                                                     Unknown                 Unknown                                                     
